IL310851A - Compounds for the treatment of diseases associated with PCSK9 activity - Google Patents
Compounds for the treatment of diseases associated with PCSK9 activityInfo
- Publication number
- IL310851A IL310851A IL310851A IL31085124A IL310851A IL 310851 A IL310851 A IL 310851A IL 310851 A IL310851 A IL 310851A IL 31085124 A IL31085124 A IL 31085124A IL 310851 A IL310851 A IL 310851A
- Authority
- IL
- Israel
- Prior art keywords
- compounds
- conditions related
- treating conditions
- pcsk9 activity
- pcsk9
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4891—Coated capsules; Multilayered drug free capsule shells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dispersion Chemistry (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163234973P | 2021-08-19 | 2021-08-19 | |
| US202163251972P | 2021-10-04 | 2021-10-04 | |
| US202163263095P | 2021-10-27 | 2021-10-27 | |
| US202263311622P | 2022-02-18 | 2022-02-18 | |
| US202263371685P | 2022-08-17 | 2022-08-17 | |
| PCT/US2022/040747 WO2023023245A1 (en) | 2021-08-19 | 2022-08-18 | Compounds for treating conditions related to pcsk9 activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL310851A true IL310851A (en) | 2024-04-01 |
Family
ID=83319263
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL310851A IL310851A (en) | 2021-08-19 | 2022-08-18 | Compounds for the treatment of diseases associated with PCSK9 activity |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240238367A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP4387645A1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP7887475B2 (cg-RX-API-DMAC10.html) |
| KR (1) | KR20240050369A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2022330007A1 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3228604A1 (cg-RX-API-DMAC10.html) |
| IL (1) | IL310851A (cg-RX-API-DMAC10.html) |
| MX (1) | MX2024002146A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2023023245A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025042927A2 (en) * | 2023-08-24 | 2025-02-27 | Merck Sharp & Dohme Llc | Sustained-release formulations for poorly permeable cyclic peptides |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3841520A1 (de) | 1988-12-09 | 1990-06-13 | Hoechst Ag | Enzymhemmende harnstoffderivate von dipeptiden, verfahren zu ihrer herstellung, diese enthaltende mittel und ihre verwendung |
| US5104869A (en) | 1989-10-11 | 1992-04-14 | American Cyanamid Company | Renin inhibitors |
| US5114937A (en) | 1989-11-28 | 1992-05-19 | Warner-Lambert Company | Renin inhibiting nonpeptides |
| US5095119A (en) | 1990-03-08 | 1992-03-10 | American Home Products Corporation | Renin inhibitors |
| WO1998039344A1 (en) | 1997-03-07 | 1998-09-11 | Metabasis Therapeutics, Inc. | Novel purine inhibitors of fructose-1,6-bisphosphatase |
| DE69819311T2 (de) | 1997-03-07 | 2004-07-29 | Metabasis Therapeutics Inc., San Diego | Neue benzimidazol inhibitoren der fructose-1,6-bisphosphatase |
| AU6691798A (en) | 1997-03-07 | 1998-09-22 | Metabasis Therapeutics, Inc. | Novel indole and azaindole inhibitors of fructose-1,6-bisphosphatase |
| CZ297264B6 (cs) | 1998-09-09 | 2006-10-11 | Metabasis Therapeutics, Inc. | Nové heteroaromatické inhibitory fruktóza-1,6-bisfosfatázy |
| CA2415742A1 (en) | 2000-07-25 | 2002-01-31 | Merck & Co., Inc. | N-substituted indoles useful in the treatment of diabetes |
| US6852738B2 (en) | 2001-01-30 | 2005-02-08 | Merck & Co., Inc. | Acyl sulfamides for treatment of obesity, diabetes and lipid disorders |
| AR040241A1 (es) | 2002-06-10 | 2005-03-23 | Merck & Co Inc | Inhibidores de la 11-beta-hidroxiesteroide deshidrogrenasa 1 para el tratamiento de la diabetes obesidad y dislipidemia |
| CA2495943C (en) | 2002-08-29 | 2009-07-21 | Merck & Co., Inc. | Indoles having anti-diabetic activity |
| WO2004019869A2 (en) | 2002-08-29 | 2004-03-11 | Merck & Co., Inc. | Indoles having anti-diabetic activity |
| CA2512879A1 (en) | 2003-01-17 | 2004-08-12 | Soumya P. Sahoo | N-cyclohexylaminocarbonyl benzenesulfonamide derivatives |
| EP2174343A1 (en) | 2007-06-28 | 2010-04-14 | Semiconductor Energy Laboratory Co, Ltd. | Manufacturing method of semiconductor device |
| US20100179173A1 (en) | 2007-06-28 | 2010-07-15 | Daniel Guay | Substituted fused pyrimidines as antagonists of gpr105 activity |
| US20110301079A1 (en) | 2007-09-21 | 2011-12-08 | Instituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Neuromedin u receptor agonists and uses thereof |
| KR20250161677A (ko) | 2018-06-21 | 2025-11-17 | 머크 샤프 앤드 돔 엘엘씨 | Pcsk9 길항제 화합물 |
| EP4021919A1 (en) * | 2019-08-30 | 2022-07-06 | Merck Sharp & Dohme Corp. | Pcsk9 antagonist compounds |
-
2022
- 2022-08-18 MX MX2024002146A patent/MX2024002146A/es unknown
- 2022-08-18 AU AU2022330007A patent/AU2022330007A1/en active Pending
- 2022-08-18 KR KR1020247008443A patent/KR20240050369A/ko active Pending
- 2022-08-18 EP EP22769816.4A patent/EP4387645A1/en active Pending
- 2022-08-18 CA CA3228604A patent/CA3228604A1/en active Pending
- 2022-08-18 WO PCT/US2022/040747 patent/WO2023023245A1/en not_active Ceased
- 2022-08-18 IL IL310851A patent/IL310851A/en unknown
- 2022-08-18 US US18/684,095 patent/US20240238367A1/en active Pending
- 2022-08-18 JP JP2024509031A patent/JP7887475B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023023245A1 (en) | 2023-02-23 |
| CA3228604A1 (en) | 2023-02-23 |
| MX2024002146A (es) | 2024-03-08 |
| JP2024532129A (ja) | 2024-09-05 |
| AU2022330007A1 (en) | 2024-02-15 |
| KR20240050369A (ko) | 2024-04-18 |
| JP7887475B2 (ja) | 2026-07-09 |
| EP4387645A1 (en) | 2024-06-26 |
| US20240238367A1 (en) | 2024-07-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL279256A (en) | Sulfonimidamide compounds as inhibitors of interleukin-1 activity | |
| IL283042A (en) | Compounds and compositions for treating conditions associated with nlrp activity | |
| MX2014013752A (es) | Inhibidores de nampt. | |
| EA201200917A1 (ru) | Пролекарства ингибиторов плазменного калликреина | |
| PH12014502513A1 (en) | Nampt inhibitors | |
| CL2021003513A1 (es) | Compuestos heterocíclicos, como inhibidores de bet; composición, útil para tratar cáncer. | |
| IN2014CN02887A (cg-RX-API-DMAC10.html) | ||
| IL290929A (en) | Transmuted cyanopyrrolidines with activity as usp30 inhibitors | |
| EP2857018C0 (en) | Treatment or prophylaxis of proliferative conditions | |
| MX348311B (es) | Inhibidores nampt. | |
| UA113198C2 (xx) | Комбінації активних сполук | |
| PH12014502757B1 (en) | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases | |
| SG190819A1 (en) | Nampt and rock inhibitors | |
| EA201390707A1 (ru) | Способ лечения контраст-индуцированной нефропатии | |
| IN2014CN04558A (cg-RX-API-DMAC10.html) | ||
| EA201790599A1 (ru) | Соединения и композиции в качестве ингибиторов киназ | |
| IN2015DN00438A (cg-RX-API-DMAC10.html) | ||
| MX2014012476A (es) | Compuestos de microarn y metodos de modulacion de la actividad de mir-21. | |
| WO2014031933A3 (en) | Heterocyclic modulators of hif activity for treatment of disease | |
| PL2589579T3 (pl) | Zastosowanie zestawu do obróbki powierzchni zaszpachlowanych gipsem, zatartych gipsem lub otynkowanych gipsem | |
| WO2014031936A3 (en) | Heterocyclic modulators of hif activity for treatment of disease | |
| EP3107626A4 (en) | Inhibitors of leukotriene-mediated activity for treating side effects of statin therapy | |
| MX348024B (es) | Compuestos de adamantilo. | |
| EA201890893A1 (ru) | Способы лечения повреждений или состояний, относящихся к отеку цнс | |
| UA108878C2 (ru) | Ингибиторы протеинтирозинкиназной активности |